--- title: "Kalshi Opens Betting on Drug Trials and FDA Decisions, Raising Insider Fears" description: "Kalshi, the CFTC-regulated prediction-market exchange, has begun letting people bet on whether drug trials succeed and whether the FDA approves new medicines, outcomes that routinely move biotech stocks. The company says safeguards protect trial integrity, but ethicists warn the contracts invite insider trading on confidential medical data, days after a separate Kalshi insider scandal." category: "Tech" category_url: https://boursel.com/category/tech author: "Hannah Blackwood" published: 2026-07-17T07:32:00.000Z updated: 2026-07-17T07:32:00.000Z canonical: https://boursel.com/article/kalshi-opens-betting-on-drug-trials-and-fda-decisions-raising-insider-fears tags: ["kalshi", "prediction-markets", "fda", "clinical-trials", "biotech"] --- # Kalshi Opens Betting on Drug Trials and FDA Decisions, Raising Insider Fears Kalshi, the CFTC-regulated prediction-market exchange, has begun letting people bet on whether drug trials succeed and whether the FDA approves new medicines, outcomes that routinely move biotech stocks. The company says safeguards protect trial integrity, but ethicists warn the contracts invite insider trading on confidential medical data, days after a separate Kalshi insider scandal. The prediction-market exchange Kalshi keeps finding new things to bet on, and its latest move touches an unusually sensitive area: medicine. The company has [begun offering contracts on the outcomes of drug trials and FDA decisions, letting users wager on whether a treatment will succeed or win approval, according to Forbes](https://www.forbes.com/sites/maryroeloffs/2026/07/16/kalshi-opens-betting-market-for-pharmaceutical-trials-and-fda-decisions/). Early markets reportedly include bets on a late-stage Alzheimer's trial and on whether regulators approve a cancer therapy. ## How this works, and why the outcomes matter Kalshi is a prediction market: an exchange, regulated by the US Commodity Futures Trading Commission, where people trade contracts that pay out based on whether a specific event happens. Instead of buying a company's shares, you buy a contract on a discrete outcome, here, "will this trial hit its goal?" or "will the FDA approve this drug?" Those outcomes are among the most powerful events in finance for a certain kind of company. A successful late-stage trial or an FDA approval can send a biotech stock soaring; a failure or rejection can cut it in half in a day. So Kalshi's contracts let traders bet directly on the news that moves biotech and pharmaceutical shares, without owning the stock. The company frames this as useful: aggregating informed opinion into a public probability of success in an industry where information is scarce. ## The insider-trading problem That is exactly what worries critics. Clinical-trial data and regulatory decisions are classic examples of material, non-public information, known to a limited circle before it becomes public. Trading on such information in the stock market is illegal insider trading, and the same logic applies to betting on it. Kalshi says it has built in safeguards: limiting the markets to late-stage trials, listing contracts only after patient enrollment closes, verifying traders' employment, and prohibiting trades based on inside information. But researchers say the risk is hard to contain. A bioethicist and an oncologist quoted by the [Boston Globe warned that the people with early sight of trial data are not just senior investigators but also doctors, nurses and staff who see patient results, any of whom could bet on what they know, and that dangling financial rewards around a clinical trial could subtly distort how it is run or interpreted](https://www.bostonglobe.com/2026/07/16/business/kalshi-biopharma-prediction-markets-clinical-trials-fda-approvals/). A deeper problem is enforcement: insider trading is usually caught long after the fact, by which point a trial's integrity may already be in question. ## Awkward timing The launch lands at a delicate moment for Kalshi. Only days earlier, the company was at the center of a different insider case: a White House teleprompter operator was placed under federal investigation for allegedly using advance sight of President Trump's speeches to win more than $100,000 on Kalshi's "mention markets," contracts on which words the president would say. Kalshi's surveillance flagged the trades, which the company points to as evidence its monitoring works, but the episode also showed how someone with privileged information can exploit these markets before being caught. ## Why it matters Prediction markets are expanding fast, from politics and sports into economics, and now into medicine and drug regulation. Each new frontier tests where society is comfortable letting people bet, and how a young, lightly regulated market polices information advantages. Betting on whether a cancer drug works raises that question in its sharpest form, mixing real money, market-moving data and patient welfare. How the CFTC responds, and whether Kalshi's safeguards hold, will shape not just this product but the credibility of prediction markets as they push into ever more consequential corners of finance. Boursel does not offer investment advice. ## Sources - [Kalshi is letting people bet on clinical trials and FDA drug decisions](https://www.forbes.com/sites/maryroeloffs/2026/07/16/kalshi-opens-betting-market-for-pharmaceutical-trials-and-fda-decisions/) - [Kalshi comes for biopharma, with prediction markets for clinical trials and FDA approvals](https://www.bostonglobe.com/2026/07/16/business/kalshi-biopharma-prediction-markets-clinical-trials-fda-approvals/)